Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated Calreticulin.

Varghese LN, Defour JP, Pecquet C, Constantinescu SN.

Front Endocrinol (Lausanne). 2017 Mar 31;8:59. doi: 10.3389/fendo.2017.00059. eCollection 2017. Review.

2.

Thrombopoietin and its receptor in normal and neoplastic hematopoiesis.

Kaushansky K.

Thromb J. 2016 Oct 4;14(Suppl 1):40. eCollection 2016.

3.

The pathophysiology of thrombocytopenia in chronic liver disease.

Mitchell O, Feldman DM, Diakow M, Sigal SH.

Hepat Med. 2016 Apr 15;8:39-50. doi: 10.2147/HMER.S74612. eCollection 2016. Review.

4.

H2S protects against fatal myelosuppression by promoting the generation of megakaryocytes/platelets.

Liu HD, Zhang AJ, Xu JJ, Chen Y, Zhu YC.

J Hematol Oncol. 2016 Feb 24;9:13. doi: 10.1186/s13045-016-0244-7.

5.

Thrombopoietin induces production of nucleated thrombocytes from liver cells in Xenopus laevis.

Tanizaki Y, Ichisugi M, Obuchi-Shimoji M, Ishida-Iwata T, Tahara-Mogi A, Meguro-Ishikawa M, Kato T.

Sci Rep. 2015 Dec 21;5:18519. doi: 10.1038/srep18519.

6.

His499 Regulates Dimerization and Prevents Oncogenic Activation by Asparagine Mutations of the Human Thrombopoietin Receptor.

Leroy E, Defour JP, Sato T, Dass S, Gryshkova V, Shwe MM, Staerk J, Constantinescu SN, Smith SO.

J Biol Chem. 2016 Feb 5;291(6):2974-87. doi: 10.1074/jbc.M115.696534. Epub 2015 Dec 1.

7.

Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene.

Wang L, Cai W, Zhang W, Chen X, Dong W, Tang D, Zhang Y, Ji C, Zhang M.

Oncotarget. 2015 Sep 29;6(29):27490-504. doi: 10.18632/oncotarget.4748.

8.

Discovery and Characterization of Nonpeptidyl Agonists of the Tissue-Protective Erythropoietin Receptor.

Miller JL, Church TJ, Leonoudakis D, Lariosa-Willingham K, Frigon NL, Tettenborn CS, Spencer JR, Punnonen J.

Mol Pharmacol. 2015 Aug;88(2):357-67. doi: 10.1124/mol.115.098400. Epub 2015 May 27.

9.
10.

Platelets and cancer: a casual or causal relationship: revisited.

Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV.

Cancer Metastasis Rev. 2014 Mar;33(1):231-69. doi: 10.1007/s10555-014-9498-0. Review.

11.

Primary thrombocytosis in children.

Kucine N, Chastain KM, Mahler MB, Bussel JB.

Haematologica. 2014 Apr;99(4):620-8. doi: 10.3324/haematol.2013.092684. Review.

12.

Requirement of TPO/c-mpl for IL-17A-induced granulopoiesis and megakaryopoiesis.

Tan W, Liu B, Barsoum A, Huang W, Kolls JK, Schwarzenberger P.

J Leukoc Biol. 2013 Dec;94(6):1303-8. doi: 10.1189/jlb.1212639. Epub 2013 Aug 29.

13.

Different mutations of the human c-mpl gene indicate distinct haematopoietic diseases.

He X, Chen Z, Jiang Y, Qiu X, Zhao X.

J Hematol Oncol. 2013 Jan 25;6:11. doi: 10.1186/1756-8722-6-11. Review.

14.

Live-cell visualization of intracellular interaction between a nuclear migration protein (hNUDC) and the thrombopoietin receptor (Mpl).

Zheng YB, Xiao YY, Tan P, Zhang Q, Xu P.

PLoS One. 2012;7(12):e51849. doi: 10.1371/journal.pone.0051849. Epub 2012 Dec 17.

15.

The molecular profiles of neural stem cell niche in the adult subventricular zone.

Lee C, Hu J, Ralls S, Kitamura T, Loh YP, Yang Y, Mukouyama YS, Ahn S.

PLoS One. 2012;7(11):e50501. doi: 10.1371/journal.pone.0050501. Epub 2012 Nov 29.

16.

Extracellular domain N-glycosylation controls human thrombopoietin receptor cell surface levels.

Albu RI, Constantinescu SN.

Front Endocrinol (Lausanne). 2011 Nov 11;2:71. doi: 10.3389/fendo.2011.00071. eCollection 2011.

17.

Thrombopoietin as biomarker and mediator of cardiovascular damage in critical diseases.

Lupia E, Goffi A, Bosco O, Montrucchio G.

Mediators Inflamm. 2012;2012:390892. doi: 10.1155/2012/390892. Epub 2012 Apr 5. Review.

18.

Thrombopoietin stimulates proliferation and megakaryocytic differentiation of mouse pro-B cell line BF-TE22.

Ohashi H, Morita H, Tahara T, Tsunakawa H, Matsumoto A, Ogami K, Kato T, Miyazaki H.

Cytotechnology. 1998 May;26(3):199-206. doi: 10.1023/A:1007915809529.

19.

A review of immune thrombocytopenic purpura: focus on the novel thrombopoietin agonists.

Khan M, Mikhael J.

J Blood Med. 2010;1:21-31. doi: 10.2147/JBM.S6803. Epub 2010 Mar 23.

20.

Effects of clinically relevant MPL mutations in the transmembrane domain revealed at the atomic level through computational modeling.

Lee TS, Kantarjian H, Ma W, Yeh CH, Giles F, Albitar M.

PLoS One. 2011;6(8):e23396. doi: 10.1371/journal.pone.0023396. Epub 2011 Aug 17.

Supplemental Content

Support Center